ARS Pharmaceuticals's total assets for Q3 2024 were $217.60M, a decrease of -1.97% from the previous quarter. SPRY total liabilities were $16.62M for the fiscal quarter, a 147.18% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.